GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Price-to-Owner-Earnings

Destiny Pharma (LSE:DEST) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Price-to-Owner-Earnings?

As of today (2024-06-09), Destiny Pharma's share price is £0.1575. Destiny Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Destiny Pharma's Price-to-Owner-Earnings or its related term are showing as below:


LSE:DEST's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Destiny Pharma's share price is £0.1575. Destiny Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.06. Therefore, Destiny Pharma's PE Ratio for today is At Loss.

As of today (2024-06-09), Destiny Pharma's share price is £0.1575. Destiny Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.06. Therefore, Destiny Pharma's PE Ratio without NRI for today is At Loss.


Destiny Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Destiny Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Price-to-Owner-Earnings Chart

Destiny Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Destiny Pharma Semi-Annual Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Destiny Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Destiny Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Destiny Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Destiny Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Destiny Pharma's Price-to-Owner-Earnings falls into.



Destiny Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Destiny Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1575/-0.07
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Destiny Pharma  (LSE:DEST) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Destiny Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Destiny Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Destiny Pharma (LSE:DEST) Business Description

Traded in Other Exchanges
Address
Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB
Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines